China moves to reform biotech policies

Jia, Hepeng
October 2004
Nature Biotechnology;Oct2004, Vol. 22 Issue 10, p1197
Academic Journal
This article focuses on Chinese government's reform measures related to biotechnology. China is going to reform how public money from different government ministries is allocated to the biotech industry through the creation of a top level biotech leadership committee, to be launched by December 2004. Meanwhile, several government departments are drafting a national plan designed to provide direction to China's biotech sector in the next two decades. Critics say these measures, which are designed to better coordinate the nation's divergent en- deavors in biotech and avoid duplication of efforts, will be effective only if the government introduces a better system to finance biotech research.


Related Articles

  • Market Overview.  // India Infrastructure Report;Q3 2008, p6 

    The article provides an overview of the economic developments and activities in India. According to the article, the state is among the fastest growing market in the world and affirms that the United Progressive Alliance (UPA) government is taking on plans to further economic reforms and develop...

  • Bell on... best of both policy worlds. Bell, Graeme // Planning (14672073);10/29/2010, Issue 1892, p7 

    The article presents an analysis on the efficiency of the regional spatial strategies used by the government in its national planning in Great Britain. The success of the spatial strategies can be achieved by consulting the views of all the parties and the parliament. The views of the parties...

  • ...while Germans flee paperwork. Toro, Taryn // New Scientist;8/8/92, Vol. 135 Issue 1833, p6 

    Reports that Germany's law regulating biotechnology is driving the industry out of the country and stifling good research in genetic engineering. Its effect on students entering the field; The law itself is not the problem but the amount of paperwork; Four categories of experiments the law covers.

  • Stolen fruit.  // New Scientist;7/24/93, Vol. 139 Issue 1883, p11 

    Reports on the Federal Bureau of Investigation's (FBI) investigation of international biotechnology espionage. Stealing of American biotechnology knowhow by foreign companies; Visit of FBI agents to companies in the San Francisco Bay area to warn them.

  • US tackles the legal labyrinth of biotechnology. Coghlan, Andy // New Scientist;7/11/92, Vol. 135 Issue 1829, p7 

    Reveals that the administration will publish a major policy document that will resolve many uncertainties over the legal maze biotechnological companies must go through. The assumption the document is based on; The document will `show once and for all who regulates what'; Some of the...

  • Prospects for new biotech regulations.  // U.S. News & World Report;3/4/91, Vol. 110 Issue 8, p14 

    Details some of the regulations suggested by the White House Council on Competitiveness (headed by Vice President Dan Quayle) that would simplify the muddled approval process for genetically engineered crops, animals and pesticides. New regulations would treat genetically altered plants the...

  • What's behind the frenetics on genetics.  // U.S. News & World Report;3/9/92, Vol. 112 Issue 9, p15 

    Details briefly the biotechnology plan that President George Bush declared last week. Genetic products are clearing the Food and Drug Administration (FDA) no more slowly than are other drugs; What the new plan will do; The battle between the Environmental Protection Agency and the Office of...

  • Overregulation could damage US biotechnology, says report. Lehrman, Sally // Nature;10/15/1992, Vol. 359 Issue 6396, p569 

    Outlines the results of a report by the National Biotechnology Policy Board which says that existing United States (US) regulations for field tests of genetically engineered organisms are stifling research. Emphasis on social costs of regulatory delays; Recommendation of a pilot study to...

  • OTA panel opens inquiry into patenting of genes. Macilwain, Colin // Nature;4/1/1993, Vol. 362 Issue 6419, p386 

    Reports that members of a panel meeting last week for the first time to advise the US Congress on gene patenting and the human genome project believe that action is needed to protect biotechnological innovation but do not agree on what should be done. Office of Technology Assessment (OTA);...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics